Belite Bio Presents Promising Results for Stargardt Disease Treatment

At the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference, Belite Bio presented new clinical and regulatory progress for its Stargardt disease drug, tinlarebant. The company reported that tinlarebant reduced annualized macular lesion growth by 35.7% in the DRAGON trial, a result described as stronger than recent geographic atrophy complement inhibitor data. While the treatment shows potential, commercial success will depend on factors such as diagnosis, reimbursement, and longer follow-up. (ng.investing.com)